Previous 10 | Next 10 |
Gainers: Neurotrope (NASDAQ: NTRP ) +126% . More news on: Neurotrope, Inc., Genprex, Inc., Trillium Therapeutics Inc., Stocks on the move, , Read more ...
One Stop Systems (NASDAQ: OSS ) +56% reports prelim results . More news on: One Stop Systems, Inc., Genprex, Inc., Akcea Therapeutics, Inc., Stocks on the move, Read more ...
January 22, 2020 Palm Beach, FL –January 22, 2020 – Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and chemotherapies; th...
Nano cap Genprex ( GNPX +308.3% ) rallies on a healthy 45x surge in volume in reaction to Fast Track status in the U.S. for immunogene therapy Oncoprex, combined with AstraZeneca's Tagrisso (osimertinib), for the treatment of patients with EGFR mutation-positive non-small cell lung cance...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that the U.S Food and Drug Administration (FDA) has granted Fast Track Designation for Genprex’s ...
Lung cancer is the world’s leading cause of cancer deaths Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor gene...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its plans to attend and present at the Biotech Showcase(TM) 2020, to be held at the Hilton San Francisco...
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced it will attend and present at the Biot...
Gene therapy is a biological product that mediates its effect by transcription and/or translation of transferred genetic material by integrating into the host genome. It is administered as nucleic acids, viruses, or genetically engineered microorganisms. In gene therapy, a normal gene is inserte...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company, on Wednesday announced a registered direct offering of 3,167,986 shares of its common stock at a price of $0.40 each, for gross proceeds of about $1.26 million prior to deduction of commissions and offering expenses. In a concurr...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...